Abstract
Objective To compare the efficacy of desloratadine citrate disodium versus loratadine in the treatment of chronic urticaria (CU) , and to evaluate their effect on serum interleukin (IL) -23, IL-33 and pulmonary and activation-regulated chemokine/CC chemokine ligand 18 (PARC/CCL-18) . Methods From January 2013 to December 2016, 120 CU patients treated in Department of Dermatology, Wuwei Oncology Hospital were enrolled into this study, and divided into study group and control group by using a random number table. Patients in the study group took oral desloratadine citrate disodium tablets 8.8 mg once a day, and patients in the control group took loratadine tablets 10 mg once a day. The treatment lasted 28 days. The therapeutic effect was compared between the two groups, and changes in serum levels of IL-23, IL-33 and PARC/CCL-18 were compared before and after treatment. Statistical analysis was carried out by using two-sample t test and chi-square test for comparing indices between the two groups. Results The response rate was significantly higher in the study group (88.33%, 53/60) than in the control group (61.67%[37/60], χ2 = 15.352, P < 0.01) . After the treatment, the serum levels of IL-23, IL-33 and PARC/CCL-18 in the study group significantly decreased to 87.72 ± 22.16 ng/L, 95.94 ± 18.27 ng/L, 85.93 ± 27.34 μg/L respectively, which were all lower than those in the control group (104.21 ± 32.05 ng/L, 106.27 ± 20.93 ng/L, 95.72 ± 30.28 μg/L, respectively; t = 3.264, 4.034, 3.934, respectively, P = 0.020, 0.006, 0.015, respectively) . No significant difference was observed in the incidence of adverse reactions between the study group and control group (P = 0.298) . Conclusion Desloratadine citrate disodium can markedly improve the clinical symptoms of CU with favorable safety, likely by inhibiting the immune response of the body and reducing the effect of chemokines on the chemotaxis of inflammatory cells. Key words: Loratadine; Urticaria; Interleukin-23; Interleukin-33; Desloratadine citrate disodium; PARC/CCL-18
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
